Lisanti Capital Growth LLC boosted its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 100.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 100,245 shares of the company’s stock after acquiring an additional 50,265 shares during the period. Lisanti Capital […]
AJOVista LLC acquired a new stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,630 shares of the company’s stock, valued at approximately $58,000. Other institutional investors also recently added to […]
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the eleven ratings firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average 12 month […]
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) saw a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 5,220,000 shares, a growth of 6.3% from the March 31st total of 4,910,000 shares. Based on an average trading volume of 802,900 shares, the days-to-cover ratio […]
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) CEO Richard Scott Struthers sold 40,951 shares of the firm’s stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $49.17, for a total transaction of $2,013,560.67. Following the transaction, the chief executive officer now directly owns 237,835 shares in […]